Identification

Name
Torasemide
Accession Number
DB00214  (APRD00295, APRD00217)
Type
Small Molecule
Groups
Approved
Description

Torasemide (rINN) or torsemide (USAN) is a pyridine-sulfonylurea type loop diuretic mainly used in the management of edema associated with congestive heart failure. It is also used at low doses for the management of hypertension. It is marketed under the brand name Demadex. [Wikipedia]

Structure
Thumb
Synonyms
  • 1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea
  • Luprac
  • N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide
  • Torasemida
  • Torasemidum
  • Torsemide
External IDs
AC-4464 / AC4464 / BM02.015
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DemadexTablet100 mg/1OralMeda Pharmaceuticals Ltd2015-01-01Not applicableUs
DemadexTablet100 mg/1OralMeda Pharmaceuticals Ltd2009-02-202016-01-20Us
DemadexTablet20 mg/1OralPhysicians Total Care, Inc.2009-10-21Not applicableUs
DemadexTablet10 mg/1OralMeda Pharmaceuticals Ltd2009-02-202016-01-20Us
DemadexTablet10 mg/1OralPhysicians Total Care, Inc.2000-11-28Not applicableUs
DemadexTablet10 mg/1OralMeda Pharmaceuticals Ltd2015-01-012019-06-30Us
DemadexTablet5 mg/1OralMeda Pharmaceuticals Ltd2009-02-202016-01-20Us
DemadexTablet20 mg/1OralMeda Pharmaceuticals Ltd2015-01-012018-11-30Us
DemadexTablet20 mg/1OralMeda Pharmaceuticals Ltd2009-02-202016-01-20Us
DemadexTablet5 mg/1OralMeda Pharmaceuticals Ltd2015-01-012018-04-05Us
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TorsemideInjection, solution10 mg/mLIntravenousGeneral Injectables & Vaccines2010-06-012017-09-29Us
TorsemideTablet10 mg/1Oralbryant ranch prepack2007-10-17Not applicableUs
TorsemideTablet10 mg/1OralCardinal Health2010-01-142018-03-09Us
TorsemideTablet100 mg/1OralAurobindo Pharma2007-10-17Not applicableUs
TorsemideTablet5 mg/1OralQualitest2011-03-222016-11-08Us
TorsemideTablet5 mg/1OralPar Pharmaceutical2009-01-272016-10-13Us
TorsemideTablet20 mg/1OralSun Pharmaceutical Industries Limited2008-02-262017-02-22Us
TorsemideTablet10 mg/1OralAv Kare, Inc.2017-04-03Not applicableUs
TorsemideTablet10 mg/1OralAv Pak2014-10-07Not applicableUs
TorsemideTablet10 mg/1OralAvera Mc Kennan Hospital2015-10-292018-06-13Us
International/Other Brands
Demadex / Diuver / Examide / Luprac
Categories
UNII
W31X2H97FB
CAS number
56211-40-6
Weight
Average: 348.42
Monoisotopic: 348.125611216
Chemical Formula
C16H20N4O3S
InChI Key
NGBFQHCMQULJNZ-UHFFFAOYSA-N
InChI
InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)
IUPAC Name
1-({4-[(3-methylphenyl)amino]pyridin-3-yl}sulfonyl)-3-(propan-2-yl)urea
SMILES
CC(C)NC(=O)NS(=O)(=O)C1=C(NC2=CC=CC(C)=C2)C=CN=C1

Pharmacology

Indication

For the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Also for the treatment of hypertension alone or in combination with other antihypertensive agents.

Associated Conditions
Pharmacodynamics

Torasemide (INN) or torsemide (USAN) is a novel loop diuretic belonging to pridine sulphonyl urea. It differs form other thiazide diuretics in that a double ring system is incorporated into its structure. Like thiazides, loop diuretics must be secreted into the tubular fluid by proximal tubule cells. In the thick ascending loop Na+ and Cl- reabsorption is accomplished by a Na+/K+/2Cl- symporter. The thick ascending limb has a high reabsorptive capacity and is responsible for reabsorbing 25% of the filtered load of Na+. The loop diuretics act by blocking this symporter. Because of the large absorptive capacity and the amount of Na+ delivered to the ascending limb, loop diuretics have a profound diuretic action. In addition, more distal nephron segments do not have the reabsorptive capacity to compensate for this increased load. The osmotic gradient for water reabsorption is also reduced resulting in an increase in the amount of water excreted.

Mechanism of action

Torasemide inhibits the Na+/K+/2Cl--carrier system (via interference of the chloride binding site) in the lumen of the thick ascending portion of the loop of Henle, resulting in a decrease in reabsorption of sodium and chloride. This results in an increase in the rate of delivery of tubular fluid and electrolytes to the distal sites of hydrogen and potassium ion secretion, while plasma volume contraction increases aldosterone production. The increased delivery and high aldosterone levels promote sodium reabsorption at the distal tubules, and By increasing the delivery of sodium to the distal renal tubule, torasemide indirectly increases potassium excretion via the sodium-potassium exchange mechanism. Torasemide's effects in other segments of the nephron have not been demonstrated. Thus torasemide increases the urinary excretion of sodium, chloride, and water, but it does not significantly alter glomerular filtration rate, renal plasma flow, or acid-base balance. Torasemide's effects as a antihypertensive are due to its diuretic actions. By reducing extracellular and plasma fluid volume, blood pressure is reduced temporarily, and cardiac output also decreases.

TargetActionsOrganism
ASolute carrier family 12 member 1
inhibitor
Human
Absorption

Rapidly absorbed following oral administration. Absolute bioavailability is 80%. Food has no effect on absorption.

Volume of distribution
  • 12 to 15 L [normal adults or in patients with mild to moderate renal failure or congestive heart failure]
Protein binding

> 99%

Metabolism

Metabolized via the hepatic CYP2C8 to 5 metabolites. The major metabolite, M5, is pharmacologically inactive. There are 2 minor metabolites, M1, possessing one-tenth the activity of torasemide, and M3, equal in activity to torasemide. Overall, torasemide appears to account for 80% of the total diuretic activity, while metabolites M1 and M3 account for 9% and 11%, respectively.

Route of elimination

Torsemide is cleared from the circulation by both hepatic metabolism (approximately 80% of total clearance) and excretion into the urine (approximately 20% of total clearance in patients with normal renal function).

Half life

3.5 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include dehydration, hypovolemia, hypotension, hyponatremia, hypokalemia, hypochloremic alkalosis, and hemoconcentration. Oral LD50 in rat is 5 g/kg, and intravenous LD50 in rat is 500 mg/kg.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Torsemide Action PathwayDrug action
Torsemide Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINEThe therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Torasemide.Experimental
(4R)-limoneneThe therapeutic efficacy of Torasemide can be decreased when used in combination with (4R)-limonene.Investigational
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Torasemide.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Torasemide.Experimental, Illicit
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Torasemide.Investigational
5-androstenedione5-androstenedione may increase the hypokalemic activities of Torasemide.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Torasemide.Experimental
AbediterolAbediterol may increase the hypokalemic activities of Torasemide.Investigational
AbirateroneThe serum concentration of Torasemide can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Torasemide.Approved, Investigational
AcebutololTorasemide may increase the hypotensive activities of Acebutolol.Approved, Investigational
AceclofenacThe therapeutic efficacy of Torasemide can be decreased when used in combination with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Torasemide can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Torasemide.Approved, Investigational, Withdrawn
Acetyl sulfisoxazoleThe metabolism of Torasemide can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Torasemide is combined with Acetyldigitoxin.Approved
AcetyldigoxinThe risk or severity of adverse effects can be increased when Torasemide is combined with Acetyldigoxin.Experimental
Acetylsalicylic acidThe therapeutic efficacy of Torasemide can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe therapeutic efficacy of Torasemide can be decreased when used in combination with Adapalene.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Torasemide.Experimental, Investigational
AlclofenacThe therapeutic efficacy of Torasemide can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlclometasoneAlclometasone may increase the hypokalemic activities of Torasemide.Approved
AlcuroniumTorasemide may decrease the neuromuscular blocking activities of Alcuronium.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Torasemide.Approved
AldosteroneAldosterone may increase the hypokalemic activities of Torasemide.Experimental, Investigational
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Torasemide.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Torasemide.Approved, Investigational
AliskirenTorasemide may increase the hypotensive activities of Aliskiren.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Torasemide.Investigational
AllopurinolThe risk or severity of adverse effects can be increased when Torasemide is combined with Allopurinol.Approved
AlminoprofenThe therapeutic efficacy of Torasemide can be decreased when used in combination with Alminoprofen.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Torasemide.Approved
AloxiprinThe therapeutic efficacy of Torasemide can be decreased when used in combination with Aloxiprin.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Torasemide.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Torasemide.Illicit
AlprenololTorasemide may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanTorasemide may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmcinonideAmcinonide may increase the hypokalemic activities of Torasemide.Approved
AmifostineTorasemide may increase the hypotensive activities of Amifostine.Approved, Investigational
AmikacinThe serum concentration of Amikacin can be increased when it is combined with Torasemide.Approved, Investigational, Vet Approved
AmilorideThe risk or severity of adverse effects can be increased when Torasemide is combined with Amiloride.Approved
Aminosalicylic AcidThe therapeutic efficacy of Torasemide can be decreased when used in combination with Aminosalicylic Acid.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Torasemide.Approved, Investigational
AmlodipineTorasemide may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Torasemide.Approved, Illicit
AmphetamineAmphetamine may increase the hypotensive activities of Torasemide.Approved, Illicit, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Torasemide is combined with Amyl Nitrite.Approved
AndrographolideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Andrographolide.Investigational
AndrostenedioneAndrostenedione may increase the hypokalemic activities of Torasemide.Experimental, Illicit
AnecortaveAnecortave may increase the hypokalemic activities of Torasemide.Investigational
anecortave acetateanecortave acetate may increase the hypokalemic activities of Torasemide.Investigational
AnisodamineThe therapeutic efficacy of Torasemide can be decreased when used in combination with Anisodamine.Investigational
AntipyrineThe therapeutic efficacy of Torasemide can be decreased when used in combination with Antipyrine.Approved, Investigational
ApalutamideThe serum concentration of Torasemide can be decreased when it is combined with Apalutamide.Approved, Investigational
ApocyninThe therapeutic efficacy of Torasemide can be decreased when used in combination with Apocynin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Torasemide.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Torasemide is combined with Apraclonidine.Approved
ApramycinThe serum concentration of Apramycin can be increased when it is combined with Torasemide.Experimental, Vet Approved
ApremilastThe therapeutic efficacy of Torasemide can be decreased when used in combination with Apremilast.Approved, Investigational
AprepitantThe metabolism of Torasemide can be increased when combined with Aprepitant.Approved, Investigational
ArbekacinThe serum concentration of Arbekacin can be increased when it is combined with Torasemide.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Torasemide.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Torasemide.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Torasemide.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Torasemide.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Torasemide.Approved, Investigational
AtamestaneAtamestane may increase the hypokalemic activities of Torasemide.Investigational
AtenololTorasemide may increase the hypotensive activities of Atenolol.Approved
AtracuriumTorasemide may decrease the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateTorasemide may decrease the neuromuscular blocking activities of Atracurium besylate.Approved
AvanafilAvanafil may increase the antihypertensive activities of Torasemide.Approved
AzapropazoneThe therapeutic efficacy of Torasemide can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Torasemide can be decreased when used in combination with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Torasemide is combined with Azilsartan medoxomil.Approved, Investigational
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Torasemide.Investigational
BalsalazideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Balsalazide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Torasemide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Torasemide.Experimental
BarbitalBarbital may increase the hypotensive activities of Torasemide.Illicit
BarnidipineTorasemide may increase the antihypertensive activities of Barnidipine.Approved
Beclomethasone dipropionateThe risk or severity of hypokalemia can be increased when Beclomethasone dipropionate is combined with Torasemide.Approved, Investigational
BekanamycinThe serum concentration of Bekanamycin can be increased when it is combined with Torasemide.Experimental
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Torasemide.Investigational
BenazeprilTorasemide may increase the hypotensive activities of Benazepril.Approved, Investigational
BendazacThe therapeutic efficacy of Torasemide can be decreased when used in combination with Bendazac.Experimental
BendroflumethiazideTorasemide may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Torasemide.Withdrawn
BenorilateThe therapeutic efficacy of Torasemide can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Torasemide can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzydamineThe therapeutic efficacy of Torasemide can be decreased when used in combination with Benzydamine.Approved
BepridilTorasemide may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneBetamethasone may increase the hypokalemic activities of Torasemide.Approved, Vet Approved
BetaxololBetaxolol may increase the hypotensive activities of Torasemide.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Torasemide.Approved
BevoniumThe therapeutic efficacy of Torasemide can be decreased when used in combination with Bevonium.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Torasemide.Experimental, Illicit, Withdrawn
BietaserpineBietaserpine may increase the hypotensive activities of Torasemide.Experimental
BimatoprostTorasemide may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisacodylThe risk or severity of adverse effects can be increased when Torasemide is combined with Bisacodyl.Approved
BisoprololTorasemide may increase the hypotensive activities of Bisoprolol.Approved
BitolterolBitolterol may increase the hypokalemic activities of Torasemide.Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Torasemide.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Torasemide.Approved, Investigational
BQ-123Torasemide may increase the hypotensive activities of BQ-123.Investigational
BretyliumTorasemide may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Torasemide.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Torasemide.Experimental
BromfenacThe therapeutic efficacy of Torasemide can be decreased when used in combination with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Torasemide.Approved, Investigational
BucillamineThe therapeutic efficacy of Torasemide can be decreased when used in combination with Bucillamine.Investigational
BudesonideThe risk or severity of hypokalemia can be increased when Budesonide is combined with Torasemide.Approved
BufexamacThe therapeutic efficacy of Torasemide can be decreased when used in combination with Bufexamac.Approved, Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Torasemide.Investigational, Withdrawn
BumadizoneThe therapeutic efficacy of Torasemide can be decreased when used in combination with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Torasemide is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Torasemide.Approved, Investigational
BupranololTorasemide may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Torasemide.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Torasemide.Approved, Illicit, Vet Approved
CadralazineCadralazine may increase the hypotensive activities of Torasemide.Experimental
CafedrineTorasemide may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinThe risk or severity of hypotension can be increased when Canagliflozin is combined with Torasemide.Approved
CandesartanTorasemide may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilThe risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Torasemide.Approved
CandoxatrilTorasemide may increase the hypotensive activities of Candoxatril.Experimental
CapecitabineThe metabolism of Torasemide can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilTorasemide may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe metabolism of Torasemide can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Torasemide can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Torasemide.Approved, Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Torasemide.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Torasemide.Illicit, Investigational, Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Torasemide.Withdrawn
CarprofenThe therapeutic efficacy of Torasemide can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololTorasemide may increase the hypotensive activities of Carteolol.Approved
CarvedilolTorasemide may increase the hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineThe therapeutic efficacy of Torasemide can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Torasemide can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Torasemide.Approved, Investigational
CeritinibThe serum concentration of Torasemide can be increased when it is combined with Ceritinib.Approved
ChloroquineThe therapeutic efficacy of Torasemide can be decreased when used in combination with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideTorasemide may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Torasemide.Approved, Investigational, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Torasemide.Approved, Investigational
ChlorthalidoneTorasemide may increase the hypotensive activities of Chlorthalidone.Approved
CholecalciferolThe metabolism of Torasemide can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Torasemide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe therapeutic efficacy of Torasemide can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Torasemide.Approved, Investigational
CicletanineTorasemide may increase the hypotensive activities of Cicletanine.Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Torasemide.Experimental
CilazaprilTorasemide may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Torasemide.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Torasemide.Approved, Investigational
CisatracuriumTorasemide may decrease the neuromuscular blocking activities of Cisatracurium.Approved
CisplatinThe risk or severity of ototoxicity and nephrotoxicity can be increased when Torasemide is combined with Cisplatin.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Torasemide.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Torasemide is combined with Clevidipine.Approved, Investigational
ClobetasolClobetasol may increase the hypokalemic activities of Torasemide.Approved, Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Torasemide.Approved
ClobetasoneClobetasone may increase the hypokalemic activities of Torasemide.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Torasemide.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Torasemide.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Torasemide.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Torasemide.Approved
ClonixinThe therapeutic efficacy of Torasemide can be decreased when used in combination with Clonixin.Approved
CloranololTorasemide may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Torasemide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Torasemide.Approved
CodeineThe therapeutic efficacy of Torasemide can be decreased when used in combination with Codeine.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Torasemide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Torasemide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Torasemide.Approved, Investigational
Cortexolone 17α-propionateCortexolone 17α-propionate may increase the hypokalemic activities of Torasemide.Investigational
CorticosteroneCorticosterone may increase the hypokalemic activities of Torasemide.Experimental
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Torasemide.Approved, Investigational
CrisaboroleThe metabolism of Torasemide can be decreased when combined with Crisaborole.Approved, Investigational
CryptenamineTorasemide may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe therapeutic efficacy of Torasemide can be decreased when used in combination with Curcumin.Approved, Investigational
CyclopenthiazideTorasemide may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Torasemide.Approved, Investigational, Vet Approved
CyclothiazideTorasemide may increase the hypotensive activities of Cyclothiazide.Approved
CymarinThe risk or severity of adverse effects can be increased when Torasemide is combined with Cymarin.Experimental
DabrafenibThe serum concentration of Torasemide can be decreased when it is combined with Dabrafenib.Approved, Investigational
DapagliflozinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Torasemide.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Torasemide.Approved, Investigational
DecamethoniumTorasemide may decrease the neuromuscular blocking activities of Decamethonium.Approved
DeferasiroxThe serum concentration of Torasemide can be increased when it is combined with Deferasirox.Approved, Investigational
DeflazacortDeflazacort may increase the hypokalemic activities of Torasemide.Approved, Investigational
DelaprilTorasemide may increase the hypotensive activities of Delapril.Investigational
DelavirdineThe metabolism of Torasemide can be decreased when combined with Delavirdine.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Torasemide.Investigational
DersalazineThe therapeutic efficacy of Torasemide can be decreased when used in combination with Dersalazine.Investigational
DeserpidineTorasemide may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Torasemide.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Torasemide is combined with Deslanoside.Approved
DesonideDesonide may increase the hypokalemic activities of Torasemide.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Torasemide.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Torasemide.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Torasemide.Experimental, Vet Approved
DexamethasoneThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Torasemide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Torasemide.Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Torasemide is combined with Dexmedetomidine.Approved, Vet Approved
DexniguldipineTorasemide may increase the hypotensive activities of Dexniguldipine.Experimental
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Torasemide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Torasemide.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Torasemide.Approved, Investigational
DiazoxideDiazoxide may increase the hypotensive activities of Torasemide.Approved
DibekacinThe serum concentration of Dibekacin can be increased when it is combined with Torasemide.Experimental
DiclofenacThe therapeutic efficacy of Torasemide can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Torasemide is combined with Diclofenamide.Approved, Investigational
DiethylnorspermineTorasemide may increase the hypotensive activities of Diethylnorspermine.Investigational
DifenpiramideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Difenpiramide.Experimental
DiflorasoneDiflorasone may increase the hypokalemic activities of Torasemide.Approved
DiflunisalThe therapeutic efficacy of Torasemide can be decreased when used in combination with Diflunisal.Approved, Investigational
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Torasemide.Approved, Investigational, Withdrawn
DifluprednateDifluprednate may increase the hypokalemic activities of Torasemide.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Torasemide is combined with Digitoxin.Approved, Investigational
DigoxinThe risk or severity of adverse effects can be increased when Torasemide is combined with Digoxin.Approved
Digoxin Immune Fab (Ovine)The risk or severity of adverse effects can be increased when Torasemide is combined with Digoxin Immune Fab (Ovine).Approved
DihydralazineDihydralazine may increase the hypotensive activities of Torasemide.Approved, Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Torasemide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Torasemide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Torasemide.Experimental, Illicit
DihydrostreptomycinThe serum concentration of Dihydrostreptomycin can be increased when it is combined with Torasemide.Investigational, Vet Approved
DiltiazemTorasemide may increase the hypotensive activities of Diltiazem.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Torasemide is combined with Dinutuximab.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Torasemide.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Torasemide.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Torasemide is combined with Dipyridamole.Approved
DobutamineDobutamine may increase the hypokalemic activities of Torasemide.Approved
DocusateThe risk or severity of adverse effects can be increased when Torasemide is combined with Docusate.Approved
DofetilideThe risk or severity of QTc prolongation, torsade de pointes, hypokalemia, hypomagnesemia, and cardiac arrest can be increased when Torasemide is combined with Dofetilide.Approved, Investigational
Domoic AcidTorasemide may decrease the neuromuscular blocking activities of Domoic Acid.Experimental
DorzolamideTorasemide may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe metabolism of Torasemide can be decreased when combined with Dosulepin.Approved
DoxacuriumTorasemide may decrease the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Torasemide.Approved
DoxofyllineDoxofylline may increase the hypokalemic activities of Torasemide.Approved, Investigational
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Torasemide.Experimental
DroxicamThe therapeutic efficacy of Torasemide can be decreased when used in combination with Droxicam.Withdrawn
DroxidopaDroxidopa may increase the hypokalemic activities of Torasemide.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Torasemide.Approved, Investigational
DuloxetineTorasemide may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe therapeutic efficacy of Torasemide can be decreased when used in combination with Duvelisib.Investigational
E-6201The therapeutic efficacy of Torasemide can be decreased when used in combination with E-6201.Investigational
EfavirenzThe metabolism of Torasemide can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineTorasemide may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Torasemide is combined with Empagliflozin.Approved
EnalaprilTorasemide may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatTorasemide may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Torasemide.Experimental
EnglitazoneThe therapeutic efficacy of Englitazone can be decreased when used in combination with Torasemide.Experimental
EpanololTorasemide may increase the hypotensive activities of Epanolol.Experimental
EphedraEphedra may increase the hypokalemic activities of Torasemide.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Torasemide.Approved, Vet Approved
EpirizoleThe therapeutic efficacy of Torasemide can be decreased when used in combination with Epirizole.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Torasemide is combined with Eplerenone.Approved
EpoprostenolTorasemide may increase the hypotensive activities of Epoprostenol.Approved
EprosartanTorasemide may increase the hypotensive activities of Eprosartan.Approved
EquileninEquilenin may increase the hypokalemic activities of Torasemide.Experimental
EquilinEquilin may increase the hypokalemic activities of Torasemide.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Torasemide.Approved
EstroneEstrone may increase the hypokalemic activities of Torasemide.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Torasemide.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Torasemide is combined with Etacrynic acid.Approved, Investigational
EtafedrineEtafedrine may increase the hypokalemic activities of Torasemide.Approved
EtanerceptThe therapeutic efficacy of Torasemide can be decreased when used in combination with Etanercept.Approved, Investigational
EthenzamideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Ethenzamide.Experimental
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Torasemide.Approved, Illicit
EtodolacThe therapeutic efficacy of Torasemide can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Torasemide can be decreased when used in combination with Etofenamate.Approved, Investigational
EtoricoxibThe therapeutic efficacy of Torasemide can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Torasemide.Illicit, Vet Approved
EtravirineThe metabolism of Torasemide can be decreased when combined with Etravirine.Approved
Evening primrose oilThe therapeutic efficacy of Torasemide can be decreased when used in combination with Evening primrose oil.Investigational, Nutraceutical
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Torasemide.Approved, Investigational
ExisulindThe therapeutic efficacy of Torasemide can be decreased when used in combination with Exisulind.Investigational
FelbinacThe therapeutic efficacy of Torasemide can be decreased when used in combination with Felbinac.Experimental
FelodipineThe metabolism of Torasemide can be decreased when combined with Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Torasemide can be decreased when used in combination with Fenbufen.Approved
FenoldopamTorasemide may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe therapeutic efficacy of Torasemide can be decreased when used in combination with Fenoprofen.Approved
FenoterolFenoterol may increase the hypokalemic activities of Torasemide.Approved, Investigational
FentanylThe therapeutic efficacy of Torasemide can be decreased when used in combination with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FentiazacThe therapeutic efficacy of Torasemide can be decreased when used in combination with Fentiazac.Experimental
FeprazoneThe therapeutic efficacy of Torasemide can be decreased when used in combination with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Torasemide can be decreased when used in combination with Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Torasemide.Approved, Investigational
FloctafenineThe therapeutic efficacy of Torasemide can be decreased when used in combination with Floctafenine.Approved, Withdrawn
FloxuridineThe metabolism of Torasemide can be decreased when combined with Floxuridine.Approved
FluasteroneFluasterone may increase the hypokalemic activities of Torasemide.Investigational
FluconazoleThe metabolism of Torasemide can be decreased when combined with Fluconazole.Approved, Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Torasemide.Approved, Investigational
FlumethasoneFlumethasone may increase the hypokalemic activities of Torasemide.Approved, Vet Approved
FlunisolideFlunisolide may increase the hypokalemic activities of Torasemide.Approved, Investigational
FlunixinThe therapeutic efficacy of Torasemide can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Torasemide can be decreased when used in combination with Flunoxaprofen.Experimental
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Torasemide.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Torasemide.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Torasemide.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Torasemide.Approved, Investigational
FluorouracilThe metabolism of Torasemide can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Torasemide can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluprednideneFluprednidene may increase the hypokalemic activities of Torasemide.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Torasemide.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Torasemide.Approved
FlurbiprofenThe therapeutic efficacy of Torasemide can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FluticasoneFluticasone may increase the hypokalemic activities of Torasemide.Approved, Experimental, Investigational
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Torasemide.Approved
Fluticasone propionateThe risk or severity of hypokalemia can be increased when Fluticasone propionate is combined with Torasemide.Approved
FluvoxamineThe metabolism of Torasemide can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneFormestane may increase the hypokalemic activities of Torasemide.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Torasemide.Approved, Investigational
FoscarnetTorasemide may decrease the excretion rate of Foscarnet which could result in a higher serum level.Approved
FosinoprilTorasemide may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinFosphenytoin may decrease the diuretic activities of Torasemide.Approved, Investigational
FostamatinibFostamatinib may increase the antihypertensive activities of Torasemide.Approved, Investigational
FramycetinThe serum concentration of Framycetin can be increased when it is combined with Torasemide.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Torasemide.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Furosemide.Approved, Vet Approved
GallamineTorasemide may decrease the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideTorasemide may decrease the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GemfibrozilThe metabolism of Torasemide can be decreased when combined with Gemfibrozil.Approved
GeneticinThe serum concentration of Geneticin can be increased when it is combined with Torasemide.Experimental
GentamicinThe serum concentration of Gentamicin can be increased when it is combined with Torasemide.Approved, Vet Approved
GENTAMICIN C1AThe serum concentration of GENTAMICIN C1A can be increased when it is combined with Torasemide.Experimental
GitoformateThe risk or severity of adverse effects can be increased when Torasemide is combined with Gitoformate.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Torasemide.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Torasemide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be increased when used in combination with Torasemide.Approved
GlipizideThe therapeutic efficacy of Glipizide can be increased when used in combination with Torasemide.Approved, Investigational
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Torasemide.Approved, Investigational
GlyburideThe therapeutic efficacy of Glyburide can be increased when used in combination with Torasemide.Approved
GlycerinThe risk or severity of adverse effects can be increased when Torasemide is combined with Glycerin.Approved, Investigational
GuacetisalThe therapeutic efficacy of Torasemide can be decreased when used in combination with Guacetisal.Experimental
GuanabenzTorasemide may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelTorasemide may increase the hypotensive activities of Guanadrel.Approved
GuanazodineTorasemide may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineTorasemide may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Torasemide.Approved, Investigational
GuanoclorTorasemide may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzTorasemide may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanTorasemide may increase the hypotensive activities of Guanoxan.Experimental
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Torasemide.Investigational
HalcinonideHalcinonide may increase the hypokalemic activities of Torasemide.Approved, Investigational, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Torasemide.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Torasemide.Experimental
HE3286HE3286 may increase the hypokalemic activities of Torasemide.Investigational
Hemoglobin crosfumarilThe therapeutic efficacy of Torasemide can be decreased when used in combination with Hemoglobin crosfumaril.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Torasemide.Approved, Illicit, Investigational
HexamethoniumTorasemide may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Torasemide.Approved
HexoprenalineHexoprenaline may increase the hypokalemic activities of Torasemide.Approved, Withdrawn
HigenamineThe therapeutic efficacy of Torasemide can be decreased when used in combination with Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Torasemide.Experimental
HydralazineHydralazine may increase the hypotensive activities of Torasemide.Approved
HydrochlorothiazideTorasemide may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe therapeutic efficacy of Torasemide can be decreased when used in combination with Hydrocodone.Approved, Illicit
HydrocortisoneThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Torasemide.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of hypokalemia can be increased when Hydrocortisone acetate is combined with Torasemide.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of hypokalemia can be increased when Hydrocortisone butyrate is combined with Torasemide.Approved, Vet Approved
HydroflumethiazideTorasemide may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Torasemide.Approved, Illicit
Hygromycin BThe serum concentration of Hygromycin B can be increased when it is combined with Torasemide.Vet Approved
IbandronateThe risk or severity of hypocalcemia can be increased when Torasemide is combined with Ibandronate.Approved, Investigational
IbuprofenThe therapeutic efficacy of Torasemide can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Torasemide can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Torasemide can be decreased when used in combination with Icatibant.Approved, Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Torasemide.Approved, Investigational
ImidaprilTorasemide may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe therapeutic efficacy of Torasemide can be decreased when used in combination with Imidazole salicylate.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Torasemide.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Torasemide.Approved
IndapamideTorasemide may increase the hypotensive activities of Indapamide.Approved
IndenololTorasemide may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Torasemide can be decreased when combined with Indinavir.Approved
IndobufenThe therapeutic efficacy of Torasemide can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Torasemide can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Torasemide can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Torasemide.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Torasemide.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Torasemide.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Torasemide.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Torasemide.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Torasemide.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Torasemide.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Torasemide.Approved
IproclozideIproclozide may increase the hypotensive activities of Torasemide.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Torasemide.Withdrawn
IrbesartanThe metabolism of Torasemide can be decreased when combined with Irbesartan.Approved, Investigational
IsepamicinThe serum concentration of Isepamicin can be increased when it is combined with Torasemide.Experimental
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Torasemide.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Torasemide.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Torasemide.Approved, Vet Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Torasemide.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Torasemide is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Torasemide is combined with Isosorbide Mononitrate.Approved
IsoxicamThe therapeutic efficacy of Torasemide can be decreased when used in combination with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Torasemide is combined with Isoxsuprine.Approved, Withdrawn
IsradipineTorasemide may increase the hypotensive activities of Isradipine.Approved, Investigational
IstaroximeIstaroxime may increase the hypokalemic activities of Torasemide.Investigational
IvabradineTorasemide may increase the arrhythmogenic activities of Ivabradine.Approved
KanamycinThe serum concentration of Kanamycin can be increased when it is combined with Torasemide.Approved, Investigational, Vet Approved
KebuzoneThe therapeutic efficacy of Torasemide can be decreased when used in combination with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Torasemide.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Torasemide.Approved, Investigational
KetoconazoleThe metabolism of Torasemide can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe therapeutic efficacy of Torasemide can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Torasemide can be decreased when used in combination with Ketorolac.Approved
LabetalolTorasemide may increase the hypotensive activities of Labetalol.Approved
LacidipineTorasemide may increase the hypotensive activities of Lacidipine.Approved, Investigational
LactuloseThe risk or severity of adverse effects can be increased when Torasemide is combined with Lactulose.Approved
Lanatoside CThe risk or severity of adverse effects can be increased when Torasemide is combined with Lanatoside C.Experimental
LapatinibThe metabolism of Torasemide can be decreased when combined with Lapatinib.Approved, Investigational
LatanoprostTorasemide may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Leflunomide.Approved, Investigational
LercanidipineTorasemide may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Torasemide is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Torasemide.Approved, Investigational
LevodopaTorasemide may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Torasemide.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Torasemide.Approved
LevosalbutamolLevosalbutamol may increase the hypokalemic activities of Torasemide.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Torasemide.Approved, Investigational
LicoriceThe risk or severity of hypokalemia can be increased when Licorice is combined with Torasemide.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Torasemide.Approved
LinsidomineTorasemide may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Torasemide.Approved
LisinoprilTorasemide may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisofyllineThe therapeutic efficacy of Torasemide can be decreased when used in combination with Lisofylline.Investigational
Lithium cationThe serum concentration of Lithium can be decreased when it is combined with Torasemide.Experimental
LobeglitazoneThe metabolism of Torasemide can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Torasemide.Illicit
LofexidineTorasemide may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe therapeutic efficacy of Torasemide can be decreased when used in combination with Lonazolac.Experimental
LornoxicamThe therapeutic efficacy of Torasemide can be decreased when used in combination with Lornoxicam.Approved, Investigational
LosartanTorasemide may increase the hypotensive activities of Losartan.Approved
LoteprednolLoteprednol may increase the hypokalemic activities of Torasemide.Approved
LovastatinThe metabolism of Torasemide can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe therapeutic efficacy of Torasemide can be decreased when used in combination with Loxoprofen.Approved, Investigational
LumacaftorThe serum concentration of Torasemide can be increased when it is combined with Lumacaftor.Approved
LumiracoxibThe therapeutic efficacy of Torasemide can be decreased when used in combination with Lumiracoxib.Approved, Investigational
MacitentanTorasemide may increase the hypotensive activities of Macitentan.Approved
Magnesium carbonateThe risk or severity of adverse effects can be increased when Torasemide is combined with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Torasemide is combined with Magnesium citrate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Torasemide is combined with Magnesium hydroxide.Approved, Investigational
Magnesium salicylateThe therapeutic efficacy of Torasemide can be decreased when used in combination with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of adverse effects can be increased when Torasemide is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineTorasemide may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Torasemide is combined with Mannitol.Approved, Investigational
MasoprocolThe therapeutic efficacy of Torasemide can be decreased when used in combination with Masoprocol.Approved, Investigational
ME-609ME-609 may increase the hypokalemic activities of Torasemide.Investigational
MebanazineMebanazine may increase the hypotensive activities of Torasemide.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Torasemide.Approved, Investigational
Meclofenamic acidThe therapeutic efficacy of Torasemide can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Torasemide.Approved
Mefenamic acidThe therapeutic efficacy of Torasemide can be decreased when used in combination with Mefenamic acid.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Torasemide.Vet Approved
MeloxicamThe therapeutic efficacy of Torasemide can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Torasemide.Experimental
MesalazineThe therapeutic efficacy of Torasemide can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Torasemide can be decreased when used in combination with Metamizole.Approved, Investigational, Withdrawn
MetforminThe therapeutic efficacy of Metformin can be increased when used in combination with Torasemide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Torasemide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Torasemide.Approved, Illicit
MethazolamideThe risk or severity of adverse effects can be increased when Torasemide is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Torasemide.Approved
MethoserpidineTorasemide may increase the hypotensive activities of Methoserpidine.Experimental
MethotrexateThe therapeutic efficacy of Torasemide can be decreased when used in combination with Methotrexate.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Torasemide is combined with Methyclothiazide.Approved
Methyl salicylateThe therapeutic efficacy of Torasemide can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
MethyldopaTorasemide may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Torasemide.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Torasemide.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Torasemide.Approved
MethylprednisoloneThe risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Torasemide.Approved, Vet Approved
MetildigoxinThe risk or severity of adverse effects can be increased when Torasemide is combined with Metildigoxin.Experimental
MetipranololTorasemide may increase the hypotensive activities of Metipranolol.Approved
MetocurineTorasemide may decrease the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideTorasemide may decrease the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MetolazoneTorasemide may increase the hypotensive activities of Metolazone.Approved
MetoprololTorasemide may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineTorasemide may increase the hypotensive activities of Metyrosine.Approved
MibefradilTorasemide may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Torasemide can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinThe serum concentration of Micronomicin can be increased when it is combined with Torasemide.Experimental
MidostaurinThe metabolism of Torasemide can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Torasemide can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Torasemide.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Torasemide.Approved
MinaprineMinaprine may increase the hypotensive activities of Torasemide.Approved
Mineral oilThe risk or severity of adverse effects can be increased when Torasemide is combined with Mineral oil.Approved, Vet Approved
MinoxidilMinoxidil may increase the hypotensive activities of Torasemide.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Torasemide.Investigational
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Torasemide.Approved, Investigational
MivacuriumTorasemide may decrease the neuromuscular blocking activities of Mivacurium.Approved
MizoribineThe therapeutic efficacy of Torasemide can be decreased when used in combination with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Torasemide.Approved, Investigational
MoexiprilTorasemide may increase the hypotensive activities of Moexipril.Approved
MofebutazoneThe therapeutic efficacy of Torasemide can be decreased when used in combination with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Torasemide.Approved, Investigational
MometasoneMometasone may increase the hypokalemic activities of Torasemide.Approved, Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Torasemide.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Torasemide.Approved, Investigational
MuzolimineTorasemide may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe therapeutic efficacy of Torasemide can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Torasemide can be decreased when used in combination with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Torasemide.Approved, Investigational
NabumetoneThe therapeutic efficacy of Torasemide can be decreased when used in combination with Nabumetone.Approved
NadololTorasemide may increase the hypotensive activities of Nadolol.Approved
NafamostatThe therapeutic efficacy of Torasemide can be decreased when used in combination with Nafamostat.Approved, Investigational
NaftifineThe therapeutic efficacy of Torasemide can be decreased when used in combination with Naftifine.Approved
NaftopidilTorasemide may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Torasemide.Approved
NaproxenThe therapeutic efficacy of Torasemide can be decreased when used in combination with Naproxen.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Torasemide.Approved, Investigational
NCX 1022NCX 1022 may increase the hypokalemic activities of Torasemide.Investigational
NeamineThe serum concentration of Neamine can be increased when it is combined with Torasemide.Experimental
NebivololTorasemide may increase the hypotensive activities of Nebivolol.Approved, Investigational
NeomycinThe serum concentration of Neomycin can be increased when it is combined with Torasemide.Approved, Vet Approved
NeosaxitoxinTorasemide may decrease the neuromuscular blocking activities of Neosaxitoxin.Investigational
NepafenacThe therapeutic efficacy of Torasemide can be decreased when used in combination with Nepafenac.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Torasemide is combined with Nesiritide.Approved, Investigational
NetilmicinThe serum concentration of Netilmicin can be increased when it is combined with Torasemide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Torasemide.Withdrawn
NicardipineThe metabolism of Torasemide can be decreased when combined with Nicardipine.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Torasemide.Experimental
NicorandilNicorandil may increase the hypotensive activities of Torasemide.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Torasemide is combined with Nicotine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Torasemide is combined with Nifedipine.Approved
NifenazoneThe therapeutic efficacy of Torasemide can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Torasemide can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineTorasemide may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Torasemide can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineTorasemide may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineTorasemide may increase the hypotensive activities of Nimodipine.Approved, Investigational
NisoldipineTorasemide may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineTorasemide may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Torasemide.Approved
NitroaspirinThe therapeutic efficacy of Torasemide can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Torasemide is combined with Nitroglycerin.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Torasemide.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Torasemide.Approved, Investigational
NorepinephrineNorepinephrine may increase the hypokalemic activities of Torasemide.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Torasemide.Approved, Illicit
ObinutuzumabTorasemide may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Torasemide.Withdrawn
OleandrinThe risk or severity of adverse effects can be increased when Torasemide is combined with Oleandrin.Experimental, Investigational
Oleoyl-estroneOleoyl-estrone may increase the hypokalemic activities of Torasemide.Investigational
OlmesartanTorasemide may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Torasemide.Approved
OlopatadineThe therapeutic efficacy of Torasemide can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Torasemide can be decreased when used in combination with Olsalazine.Approved
OmapatrilatTorasemide may increase the hypotensive activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Torasemide.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Torasemide.Approved
OrgoteinThe therapeutic efficacy of Torasemide can be decreased when used in combination with Orgotein.Vet Approved
OuabainThe risk or severity of adverse effects can be increased when Torasemide is combined with Ouabain.Approved
OxaprozinThe therapeutic efficacy of Torasemide can be decreased when used in combination with Oxaprozin.Approved
OxprenololTorasemide may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe therapeutic efficacy of Torasemide can be decreased when used in combination with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe therapeutic efficacy of Torasemide can be decreased when used in combination with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenbutazoneThe therapeutic efficacy of Torasemide can be decreased when used in combination with Oxyphenbutazone.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Torasemide.Approved, Vet Approved
PalmidrolThe therapeutic efficacy of Torasemide can be decreased when used in combination with Palmidrol.Experimental, Nutraceutical
PancuroniumTorasemide may decrease the neuromuscular blocking activities of Pancuronium.Approved
PapaverineThe risk or severity of adverse effects can be increased when Torasemide is combined with Papaverine.Approved, Investigational
ParamethasoneParamethasone may increase the hypokalemic activities of Torasemide.Approved
ParecoxibThe therapeutic efficacy of Torasemide can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Torasemide.Approved
ParomomycinThe serum concentration of Paromomycin can be increased when it is combined with Torasemide.Approved, Investigational
ParthenolideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Parthenolide.Approved, Investigational
PenbutololTorasemide may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Torasemide.Approved, Vet Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Torasemide.Approved, Investigational, Vet Approved
PentoliniumTorasemide may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Torasemide.Approved, Investigational
PerindoprilTorasemide may increase the hypotensive activities of Perindopril.Approved
PeruvosideThe risk or severity of adverse effects can be increased when Torasemide is combined with Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Torasemide.Approved
PF-00610355PF-00610355 may increase the hypokalemic activities of Torasemide.Investigational
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Torasemide.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Torasemide.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Torasemide.Approved, Investigational, Withdrawn
PheniprazinePheniprazine may increase the hypotensive activities of Torasemide.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Torasemide.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Torasemide.Experimental
PhenoxybenzamineTorasemide may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Torasemide.Withdrawn
PhentolamineTorasemide may increase the hypotensive activities of Phentolamine.Approved
Phenyl aminosalicylateThe therapeutic efficacy of Torasemide can be decreased when used in combination with Phenyl aminosalicylate.Approved
PhenylbutazoneThe therapeutic efficacy of Torasemide can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Torasemide.Approved, Vet Approved, Withdrawn
PhenytoinPhenytoin may decrease the diuretic activities of Torasemide.Approved, Vet Approved
PimecrolimusThe therapeutic efficacy of Torasemide can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Torasemide.Approved
PindololTorasemide may increase the hypotensive activities of Pindolol.Approved, Investigational
PioglitazoneThe metabolism of Torasemide can be decreased when combined with Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Torasemide.Approved, Investigational
PipecuroniumTorasemide may decrease the neuromuscular blocking activities of Pipecuronium.Approved
PirbuterolPirbuterol may increase the hypokalemic activities of Torasemide.Approved
PirfenidoneThe therapeutic efficacy of Torasemide can be decreased when used in combination with Pirfenidone.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Torasemide.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Torasemide.Approved
PiroxicamThe therapeutic efficacy of Torasemide can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Torasemide can be decreased when used in combination with Pirprofen.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Torasemide.Withdrawn
Platelet Activating FactorTorasemide may increase the hypotensive activities of Platelet Activating Factor.Experimental
PlazomicinThe serum concentration of Plazomicin can be increased when it is combined with Torasemide.Approved, Investigational
PolythiazideTorasemide may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Torasemide.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Torasemide.Approved, Investigational
PranoprofenThe therapeutic efficacy of Torasemide can be decreased when used in combination with Pranoprofen.Experimental, Investigational
PrasteronePrasterone may increase the hypokalemic activities of Torasemide.Approved, Investigational, Nutraceutical
Prasterone sulfatePrasterone sulfate may increase the hypokalemic activities of Torasemide.Investigational
PrazosinPrazosin may increase the hypotensive activities of Torasemide.Approved
PrednicarbatePrednicarbate may increase the hypokalemic activities of Torasemide.Approved, Investigational
PrednisoloneThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Torasemide.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Torasemide.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Torasemide.Approved, Experimental, Investigational
PrimidoneThe metabolism of Torasemide can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe risk or severity of adverse effects can be increased when Probenecid is combined with Torasemide.Approved, Investigational
ProcaineProcaine may increase the hypotensive activities of Torasemide.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Torasemide.Approved, Investigational
ProcaterolProcaterol may increase the hypokalemic activities of Torasemide.Approved, Investigational
ProglumetacinThe therapeutic efficacy of Torasemide can be decreased when used in combination with Proglumetacin.Experimental
PropacetamolThe therapeutic efficacy of Torasemide can be decreased when used in combination with Propacetamol.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Torasemide.Approved, Investigational, Vet Approved
PropranololTorasemide may increase the hypotensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Torasemide can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Torasemide can be decreased when used in combination with Proquazone.Experimental
ProscillaridinThe risk or severity of adverse effects can be increased when Torasemide is combined with Proscillaridin.Experimental
ProtokylolProtokylol may increase the hypokalemic activities of Torasemide.Approved, Vet Approved
PTC299The therapeutic efficacy of Torasemide can be decreased when used in combination with PTC299.Investigational
PuromycinThe serum concentration of Puromycin can be increased when it is combined with Torasemide.Experimental
PyrantelTorasemide may decrease the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
PyrimethamineThe metabolism of Torasemide can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Torasemide is combined with Quetiapine.Approved
QuinaprilTorasemide may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineThe metabolism of Torasemide can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Torasemide can be decreased when combined with Rabeprazole.Approved, Investigational
RacepinephrineRacepinephrine may increase the hypokalemic activities of Torasemide.Approved
RamiprilTorasemide may increase the hypotensive activities of Ramipril.Approved
RapacuroniumTorasemide may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Torasemide.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Torasemide.Approved
RemikirenRemikiren may increase the hypotensive activities of Torasemide.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Torasemide.Approved, Investigational
RescinnamineTorasemide may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Torasemide.Approved, Investigational
ResveratrolThe therapeutic efficacy of Torasemide can be decreased when used in combination with Resveratrol.Approved, Experimental, Investigational
RibostamycinThe serum concentration of Ribostamycin can be increased when it is combined with Torasemide.Approved, Investigational
RifampicinThe metabolism of Torasemide can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Torasemide can be increased when combined with Rifapentine.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Torasemide.Approved, Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Torasemide.Approved
RiociguatTorasemide may increase the hypotensive activities of Riociguat.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Torasemide is combined with Risperidone.Approved, Investigational
RitodrineRitodrine may increase the hypokalemic activities of Torasemide.Approved, Investigational
RituximabTorasemide may increase the hypotensive activities of Rituximab.Approved
RocuroniumTorasemide may decrease the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibThe therapeutic efficacy of Torasemide can be decreased when used in combination with Rofecoxib.Approved, Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Torasemide.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Torasemide.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be increased when used in combination with Torasemide.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Torasemide.Approved
RucaparibThe metabolism of Torasemide can be decreased when combined with Rucaparib.Approved, Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Torasemide.Approved
SafrazineSafrazine may increase the hypotensive activities of Torasemide.Withdrawn
SalbutamolThe risk or severity of hyperkalemia can be increased when Salbutamol is combined with Torasemide.Approved, Vet Approved
SalicylamideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Torasemide can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalmeterolThe risk or severity of hyperkalemia can be increased when Salmeterol is combined with Torasemide.Approved
SalsalateThe therapeutic efficacy of Torasemide can be decreased when used in combination with Salsalate.Approved
SaprisartanTorasemide may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinThe therapeutic efficacy of Saxagliptin can be increased when used in combination with Torasemide.Approved
SecobarbitalThe metabolism of Torasemide can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Torasemide.Approved, Investigational, Vet Approved
SelexipagTorasemide may increase the hypotensive activities of Selexipag.Approved
SemapimodThe therapeutic efficacy of Torasemide can be decreased when used in combination with Semapimod.Investigational
SeratrodastThe therapeutic efficacy of Torasemide can be decreased when used in combination with Seratrodast.Approved
SerrapeptaseThe therapeutic efficacy of Torasemide can be decreased when used in combination with Serrapeptase.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Torasemide.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Torasemide.Approved, Investigational
SisomicinThe serum concentration of Sisomicin can be increased when it is combined with Torasemide.Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be increased when used in combination with Torasemide.Approved, Investigational
SitaxentanTorasemide may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium phosphate, monobasicTorasemide may increase the nephrotoxic activities of Sodium phosphate, monobasic.Approved
SorafenibThe metabolism of Torasemide can be decreased when combined with Sorafenib.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Torasemide.Investigational
SotalolThe risk or severity of adverse effects can be increased when Torasemide is combined with Sotalol.Approved
SpiraprilTorasemide may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Torasemide is combined with Spironolactone.Approved
SRT501The therapeutic efficacy of Torasemide can be decreased when used in combination with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Torasemide.Approved, Investigational
StreptomycinThe serum concentration of Streptomycin can be increased when it is combined with Torasemide.Approved, Vet Approved
SuccinylcholineTorasemide may decrease the neuromuscular blocking activities of Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Torasemide.Approved, Investigational
SulfadiazineThe metabolism of Torasemide can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Torasemide can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe therapeutic efficacy of Torasemide can be decreased when used in combination with Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Torasemide can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe therapeutic efficacy of Torasemide can be decreased when used in combination with Sulindac.Approved, Investigational
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Torasemide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Torasemide is combined with Sulpiride.Approved, Investigational
SuprofenThe therapeutic efficacy of Torasemide can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Torasemide can be decreased when used in combination with Suxibuzone.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Torasemide.Approved, Investigational
TalinololTorasemide may increase the hypotensive activities of Talinolol.Investigational
TamoxifenThe metabolism of Torasemide can be decreased when combined with Tamoxifen.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Torasemide.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Torasemide.Approved
TarenflurbilThe therapeutic efficacy of Torasemide can be decreased when used in combination with Tarenflurbil.Investigational
TelmisartanTorasemide may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilTorasemide may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapThe therapeutic efficacy of Torasemide can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Torasemide can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Torasemide can be decreased when used in combination with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Torasemide is combined with Terazosin.Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Torasemide.Approved
TeriflunomideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Teriflunomide.Approved
TerlipressinTorasemide may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineTorasemide may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Torasemide.Approved, Investigational, Withdrawn
TheodrenalineTorasemide may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineTheophylline may increase the antihypertensive activities of Torasemide.Approved
ThiamylalThiamylal may increase the hypotensive activities of Torasemide.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Torasemide.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Torasemide.Approved, Withdrawn
Tiaprofenic acidThe therapeutic efficacy of Torasemide can be decreased when used in combination with Tiaprofenic acid.Approved
TiboloneTorasemide may increase the hypotensive activities of Tibolone.Approved, Investigational
TicagrelorThe metabolism of Torasemide can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Torasemide can be decreased when combined with Ticlopidine.Approved
TicrynafenTorasemide may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Torasemide.Experimental
TimololTorasemide may increase the hypotensive activities of Timolol.Approved
TinoridineThe therapeutic efficacy of Torasemide can be decreased when used in combination with Tinoridine.Investigational
TixocortolTixocortol may increase the hypokalemic activities of Torasemide.Approved, Withdrawn
TizanidineThe risk or severity of adverse effects can be increased when Torasemide is combined with Tizanidine.Approved, Investigational
TobramycinThe serum concentration of Tobramycin can be increased when it is combined with Torasemide.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Torasemide.Approved, Investigational
TolazolineTorasemide may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Torasemide can be decreased when combined with Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Torasemide.Approved, Withdrawn
Tolfenamic AcidThe therapeutic efficacy of Torasemide can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
TolmetinThe therapeutic efficacy of Torasemide can be decreased when used in combination with Tolmetin.Approved
TolonidineTorasemide may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Torasemide.Approved
TopiramateThe risk or severity of hypokalemia can be increased when Torasemide is combined with Topiramate.Approved
TopiroxostatThe metabolism of Torasemide can be decreased when combined with Topiroxostat.Approved, Investigational
TramadolThe therapeutic efficacy of Torasemide can be decreased when used in combination with Tramadol.Approved, Investigational
TrandolaprilTorasemide may increase the hypotensive activities of Trandolapril.Approved
TranylcypromineTranylcypromine may increase the hypotensive activities of Torasemide.Approved, Investigational
TravoprostTorasemide may increase the hypotensive activities of Travoprost.Approved
TreprostinilTorasemide may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Torasemide.Approved, Investigational, Nutraceutical
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Torasemide.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Torasemide is combined with Triamterene.Approved
TribenosideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Tribenoside.Experimental
TrichlormethiazideTorasemide may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Torasemide.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Torasemide.Approved, Investigational
TrimethoprimThe metabolism of Torasemide can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptolideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Triptolide.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Torasemide.Investigational, Withdrawn
Trolamine salicylateThe therapeutic efficacy of Torasemide can be decreased when used in combination with Trolamine salicylate.Approved
TubocurarineTorasemide may decrease the neuromuscular blocking activities of Tubocurarine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Torasemide.Approved, Investigational
UlobetasolUlobetasol may increase the hypokalemic activities of Torasemide.Approved
UnoprostoneTorasemide may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Torasemide.Investigational
ValdecoxibThe therapeutic efficacy of Torasemide can be decreased when used in combination with Valdecoxib.Approved, Investigational, Withdrawn
Valproic AcidThe metabolism of Torasemide can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Torasemide can be decreased when combined with Valsartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Torasemide.Approved
VecuroniumTorasemide may decrease the neuromuscular blocking activities of Vecuronium.Approved
VemurafenibThe serum concentration of Torasemide can be increased when it is combined with Vemurafenib.Approved
VerapamilThe risk or severity of adverse effects can be increased when Torasemide is combined with Verapamil.Approved
VilanterolVilanterol may increase the hypokalemic activities of Torasemide.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Torasemide.Approved, Investigational
VincamineTorasemide may increase the hypotensive activities of Vincamine.Experimental
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Torasemide.Approved, Investigational
VoriconazoleThe metabolism of Torasemide can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinThe metabolism of Warfarin can be decreased when combined with Torasemide.Approved
XipamideTorasemide may increase the hypotensive activities of Xipamide.Experimental
XylometazolineTorasemide may increase the hypotensive activities of Xylometazoline.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Torasemide.Approved, Investigational, Vet Approved
ZafirlukastThe metabolism of Torasemide can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe therapeutic efficacy of Torasemide can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ZileutonThe therapeutic efficacy of Torasemide can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilTorasemide may increase the hypotensive activities of Zofenopril.Experimental
Zoledronic acidThe risk or severity of hypocalcemia can be increased when Torasemide is combined with Zoledronic acid.Approved
ZomepiracThe therapeutic efficacy of Torasemide can be decreased when used in combination with Zomepirac.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Fritz Topfmeier, Gustav Lettenbauer, "Process for the preparation of a stable modification of torasemide." U.S. Patent USRE0345806, issued June, 1975.

USRE0345806
General References
  1. Dunn CJ, Fitton A, Brogden RN: Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs. 1995 Jan;49(1):121-42. [PubMed:7705212]
  2. Authors unspecified: FDA approved new drug bulletin: torsemide (Demadex), trimetrexate glucuronate (neuTrexin). RN. 1994 May;57(5):53-6. [PubMed:8197389]
External Links
Human Metabolome Database
HMDB0014359
KEGG Drug
D00382
PubChem Compound
41781
PubChem Substance
46504760
ChemSpider
38123
BindingDB
64107
ChEBI
9637
ChEMBL
CHEMBL1148
Therapeutic Targets Database
DAP000745
PharmGKB
PA451733
RxList
RxList Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Torasemide
ATC Codes
C03CA04 — TorasemideG01AE10 — Combinations of sulfonamides
MSDS
Download (110 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedNot AvailableTo Determine Bioequivalence Under Fasting Conditions1
1CompletedBasic ScienceDrug Biotransformation / Membrane Transport1
1CompletedBasic ScienceGenotype-related Drug Metabolism1
1CompletedTreatmentChronic Kidney Disease (CKD) / Congestive Heart Failure (CHF)1
1CompletedTreatmentType 2 Diabetes Mellitus1
1Not Yet RecruitingTreatmentBody Weight Changes1
1TerminatedTreatmentHeart Failure, Unspecified / Impaired Renal Function1
2RecruitingPreventionPreeclampsia1
2, 3CompletedTreatmentHeart Failure, Unspecified1
2, 3RecruitingHealth Services ResearchAcute Heart Failure (AHF)1
3RecruitingTreatmentHeart Failure, Unspecified1
4CompletedTreatmentHigh Blood Pressure (Hypertension)2
4CompletedTreatmentRight Heart Failure / Tricuspid valve incompetence1
4Enrolling by InvitationTreatmentHeart Failure, Unspecified1
4RecruitingTreatmentCardiovascular Disease (CVD) / High Blood Pressure (Hypertension)1
4RecruitingTreatmentHeart Failure, Unspecified1
4Unknown StatusTreatmentArterial Hypertension / Chronic Heart Failure (CHF)1
Not AvailableCompletedTreatmentEdema2
Not AvailableTerminatedDiagnosticAcute Decompensated Heart Failure (ADHF)1

Pharmacoeconomics

Manufacturers
  • Hoffmann la roche inc
  • Bedford laboratories
  • Luitpold pharmaceuticals inc
  • Meda pharmaceuticals inc
  • Apotex inc etobicoke site
  • Aurobindo pharma ltd
  • Hetero drugs ltd
  • Par pharmaceutical inc
  • Pliva pharmaceutical industry inc
  • Roxane laboratories inc
  • Sun pharmaceutical industries ltd
  • Teva pharmaceuticals usa inc
Packagers
  • American Regent
  • Apotex Inc.
  • Aurobindo Pharma Ltd.
  • Camber Pharmaceuticals Inc.
  • Cardinal Health
  • Diversified Healthcare Services Inc.
  • F Hoffmann-La Roche Ltd.
  • General Injectables and Vaccines Inc.
  • Greenstone LLC
  • Heartland Repack Services LLC
  • Hetero Drugs Ltd.
  • Ivax Pharmaceuticals
  • Mckesson Corp.
  • Meda AB
  • Murfreesboro Pharmaceutical Nursing Supply
  • Neuman Distributors Inc.
  • Palmetto Pharmaceuticals Inc.
  • Par Pharmaceuticals
  • Physicians Total Care Inc.
  • Pliva Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepak Systems Inc.
  • Resource Optimization and Innovation LLC
  • Roxane Labs
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Vangard Labs Inc.
Dosage forms
FormRouteStrength
TabletOral10 mg/1
TabletOral100 mg/1
TabletOral20 mg/1
TabletOral5 mg/1
LiquidIntravenous10 mg
TabletOral100 mg
TabletOral10 mg
TabletOral20 mg
TabletOral5 mg
InjectionIntravenous10 mg/mL
Injection, solutionIntravenous10 mg/mL
Prices
Unit descriptionCostUnit
Demadex 100 mg tablet5.69USD tablet
Torsemide 100 mg tablet3.16USD tablet
Demadex 20 mg tablet1.59USD tablet
Demadex 10 mg tablet1.39USD tablet
Demadex 5 mg tablet1.28USD tablet
Torsemide 20 mg tablet0.85USD tablet
Torsemide 10 mg tablet0.73USD tablet
Torsemide 5 mg tablet0.66USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)164-164 °CNot Available
water solubilityWater solubleNot Available
logP2.3Not Available
pKa7.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0596 mg/mLALOGPS
logP1.76ALOGPS
logP1.86ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)5.92ChemAxon
pKa (Strongest Basic)4.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area100.19 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity91.89 m3·mol-1ChemAxon
Polarizability36.15 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier+0.6871
Caco-2 permeable-0.5374
P-glycoprotein substrateNon-substrate0.799
P-glycoprotein inhibitor INon-inhibitor0.7695
P-glycoprotein inhibitor IINon-inhibitor0.8232
Renal organic cation transporterNon-inhibitor0.9185
CYP450 2C9 substrateSubstrate0.6049
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7558
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.6692
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.5905
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6324
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8366
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.8740 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9854
hERG inhibition (predictor II)Non-inhibitor0.8668
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03di-0090000000-bcaf4981571fb662df86
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03di-0090000000-00cc7369c05298ea1c97
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03di-0490000000-60171fe07a2f255596e3
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-01ot-2950000000-359d6835f9bf703a0701
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000t-3910000000-a5ec65a6dbedfe7a30d3
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0564-6900000000-051171526b146f5d076c
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03di-0190000000-1b2efe76058c7bf06b4a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0091000000-548edfa45514c501788d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0090000000-d7326b2b38380cd06e26
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0490000000-b9f43c4768937947d77f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-0940000000-7b7084526f7c13bf6443
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00lr-0910000000-81aa8c9ff5d9a3cd3c10
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0159-0900000000-87860a9931a8414432cf
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-1590000000-1b7d966c20cec1451f6c
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0490000000-bd8b6af3fe8d0f10e117
MS/MS Spectrum - , positiveLC-MS/MSsplash10-02ai-2940000000-5beb0e7e25d393903803
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0390000000-314819093d7d5a1f48f4

Taxonomy

Description
This compound belongs to the class of organic compounds known as pyridinesulfonamides. These are heterocyclic compounds containing a pyridine ring substituted by one or more sulfonamide groups.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Pyridinesulfonamides
Direct Parent
Pyridinesulfonamides
Alternative Parents
Toluenes / Sulfonylureas / Dihydropyridines / Secondary ketimines / Organosulfonic acids and derivatives / Heteroaromatic compounds / Aminosulfonyl compounds / Propargyl-type 1,3-dipolar organic compounds / Carboximidic acids and derivatives / Azacyclic compounds
show 4 more
Substituents
Pyridine-3-sulfonamide / Dihydropyridine / Toluene / Sulfonylurea / Monocyclic benzene moiety / Hydropyridine / Benzenoid / Secondary ketimine / Heteroaromatic compound / Organic sulfonic acid or derivatives
show 16 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
secondary amino compound, aminopyridine, N-sulfonylurea (CHEBI:9637)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A1
Uniprot ID
Q13621
Uniprot Name
Solute carrier family 12 member 1
Molecular Weight
121449.13 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Vormfelde SV, Sehrt D, Toliat MR, Schirmer M, Meineke I, Tzvetkov M, Nurnberg P, Brockmoller J: Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9. Epub 2007 Apr 25. [PubMed:17460608]
  3. Fortuno A, Muniz P, Ravassa S, Rodriguez JA, Fortuno MA, Zalba G, Diez J: Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension. 1999 Jul;34(1):138-43. [PubMed:10406837]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 04:17